Why Did Netflix Buy Warner Bros?
Following a bidding war, Netflix (NASDAQ:NFLX) has announced its intention…
Sell
31
INCR Quote, Financials, Valuation and Earnings
Last price:
$1.29
Seasonality move
:
4.38%
Day range:
$1.28 - $1.30
52-week range:
$1.22 - $1.79
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.50x
P/B ratio:
0.52x
Volume:
4.2K
Avg. volume:
16.1K
1-year change:
-8.51%
Market cap:
$71M
Revenue:
$64.5M
EPS (TTM):
-$0.11
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, InterCure Ltd. has 7.77% upside to fair value with a price target of -- per share.
INCR vs. S&P 500
-
Over the past 5 trading days, InterCure Ltd. has underperformed the S&P 500 by -2.28% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
InterCure Ltd. does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
InterCure Ltd. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter InterCure Ltd. reported revenues of --.
Earnings Growth
-
InterCure Ltd. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter InterCure Ltd. reported earnings per share of --.
Enterprise value:
88.6M
EV / Invested capital:
--
Price / LTM sales:
0.50x
EV / EBIT:
9.94x
EV / Revenue:
0.75x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-8.13x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
6.95x
Gross Profit (TTM):
$10.9M
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2022-06-30 | 2023-06-30 | |
| Income Statement | ||||||
| Revenue | $38.7M | $100.1M | $117.9M | $28.4M | $28.1M | |
| Gross Profit | $17.6M | $43.4M | $40.4M | $12.4M | $9M | |
| Operating Income | $6.6M | $18.3M | $8.9M | $5M | $1.9M | |
| EBITDA | $8.2M | $21.3M | $12.8M | $5.7M | $2.8M | |
| Diluted EPS | $0.20 | $0.16 | $0.13 | $0.10 | $0.03 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $23.9M | $108M | $143.8M | -- | $107.3M | |
| Total Assets | $101.6M | $223.8M | $271.5M | -- | $208.7M | |
| Current Liabilities | $9.3M | $62.2M | $88.6M | -- | $62.1M | |
| Total Liabilities | $10.6M | $73M | $123.7M | -- | $99.9M | |
| Total Equity | $91M | $150.8M | $147.8M | -- | $108.9M | |
| Total Debt | $1.7M | $11.8M | $36M | -- | $50.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2022-03-31 | 2023-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $5.9M | $6.2M | -$6.9M | $658.1K | -$16M | |
| Cash From Investing | -$6.6M | -$15.5M | -$44.9M | -$3M | -$4.1M | |
| Cash From Financing | $7.5M | $69.5M | $19.2M | $5.9M | -$15.6M | |
| Free Cash Flow | $730.6K | $454.3K | -$10.9M | -$1.5M | -$16.2M | |
INCR
Sector
Market Cap
$71M
$28.5M
Price % of 52-Week High
72.58%
51.43%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.33%
1-Year Price Total Return
-8.52%
-21.18%
Beta (5-Year)
0.600
0.519
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.33
200-day SMA
Sell
Level
$1.50
Bollinger Bands (100)
Sell
Level
1.38 - 1.62
Chaikin Money Flow
Sell
Level
-1.1M
20-day SMA
Sell
Level
$1.34
Relative Strength Index (RSI14)
Sell
Level
40.51
ADX Line
Sell
Level
16.9
Williams %R
Neutral
Level
-77.3795
50-day SMA
Sell
Level
$1.45
MACD (12, 26)
Sell
Level
-0.03
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Neutral
Level
5.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.1528)
Sell
CA Score
(Annual)
Level (-0.5912)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (1.4125)
Sell
Piotroski F Score
(Annual)
Level (1)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
InterCure Ltd. engages in the provision of business of medical cannabis and biomedicine. It operates through the Investments in Biomed Portfolio Companies in the Biomed Sector and Investments in the Medical Cannabis Sector segments. The company was founded by Benjamin Gavish and Erez Gavish on November 20, 1994 and is headquartered in Herzliya, Israel.
Stock Forecast FAQ
In the current month, INCR has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The INCR average analyst price target in the past 3 months is --.
-
Where Will InterCure Ltd. Stock Be In 1 Year?
According to analysts, the consensus estimate is that InterCure Ltd. share price will rise to -- per share over the next 12 months.
-
What Do Analysts Say About InterCure Ltd.?
Analysts are divided on their view about InterCure Ltd. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that InterCure Ltd. is a Sell and believe this share price will drop from its current level to --.
-
What Is InterCure Ltd.'s Price Target?
The price target for InterCure Ltd. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is INCR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for InterCure Ltd. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of INCR?
You can purchase shares of InterCure Ltd. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase InterCure Ltd. shares.
-
What Is The InterCure Ltd. Share Price Today?
InterCure Ltd. was last trading at $1.29 per share. This represents the most recent stock quote for InterCure Ltd.. Yesterday, InterCure Ltd. closed at $1.30 per share.
-
How To Buy InterCure Ltd. Stock Online?
In order to purchase InterCure Ltd. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get INCR Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
INCR
Sector
P/E ratio
--
23.66x
PEG ratio
--
-0.01x
P/B ratio
0.52x
1.82x
Price / LTM sales
0.50x
1.61x
Growth Metrics
INCR
Sector
Revenue growth
--
4.8%
Earnings growth
--
11.11%
Revenue (5-year growth)
91.5%
6.45%
Earnings forecast
--
-$0.20
Profitability
INCR
Sector
Profitability FY 2024
$3.8M
$3.6M
Return on invested capital
--
-31.15%
Return on assets
--
-27.72%
Return on equity
--
-36.72%
Earnings Date
Last Earnings Date
May
2
Next Earnings Date
Dec
9
Estimated Next Earnings Date
Mar
10
Balance Sheet
INCR
Sector
Total cash
$5.4M
$27M
Short term investments
$91.2K
$25.7M
Total assets
$209.3M
$79.7M
Long term debt
$35.3M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
67
GPCR alert for Dec 9
Structure Therapeutics, Inc. [GPCR] is down 2.26% over the past day.
Buy
62
SMX alert for Dec 9
SMX (Security Matters) Plc [SMX] is up 2.34% over the past day.
Buy
90
KYMR alert for Dec 9
Kymera Therapeutics, Inc. [KYMR] is down 7.55% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
